Last updated: 2026-09-16 12:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Telomir Pharmaceuticals, Inc. (TELO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.15, with a market capitalisation of $80.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.89 to $2.09. This page covers its latest market performance, valuation, price trends and company information.
$80.47M | |
$1.21 | |
$20.72 | |
$0.89 | |
$1.17 | |
159.00 | |
90.32K | |
-- | |
$2.09 | |
$0.89 | |
-- | |
-- |
Telomir Pharmaceuticals, Inc. (TELO) is trading at $1.15 in pre-market trading as of 2026-09-16 11:03:00, down 2.05% ($0.02) from the previous close of $1.17
Pre-market trading shows how investors are pricing TELO before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Telomir Pharmaceuticals, Inc. (TELO) moved from $1.16 to $1.15, representing a decline of 1.21% ($0.01).
The stock traded between $1.11 and $1.23 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 40.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 21.4%
TELO is currently trading at $1.15, placing it 21.4% of the way from its 52-week low of $0.89 to its 52-week high of $2.09. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Telomir Pharmaceuticals, Inc. (TELO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.